INTEGRA Dermal Regeneration Template, Integra Meshed Dermal Regeneration Template, and Integra Omnigraft Dermal Regen
Integra Lifesciences Corp. · Decision date Sep 9, 2025
What did the FDA decide?
FDA records P900033/S115 as a supplement to PMA P900033, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 9, 2025.
FDA approval order statement
reclassifying cleanroom for Integra Dermal Regeneration Template (IDRT) product family
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 9, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P900033/S115
- Regulatory pathway
- PMA supplement
- Applicant
- Integra Lifesciences Corp.
- Product code
- MGR
- Decision code
- OK30
- Decision date
- Sep 9, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Dressing, wound and burn, interactive.
- Applicant
- Integra Lifesciences Corp.
- Product code
- MGR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P900033. Subsequent supplements may change the device or its indications.
FDA decision timeline
P900033 · Original PMA
INTEGRA DERMAL REGENERATION TEMPLATE
P900033/S115 received
Application receipt date recorded by FDA.
P900033/S115 · FDA decision
30-Day Notice
P900033/S116 · Related supplement
INTEGRA Dermal Regeneration Template; Integra Meshed Dermal Regeneration Template; Integra Omnigraft Dermal Regenera
P900033/S117 · Related supplement
INTEGRA Dermal Regeneration Template, Integra Meshed Dermal Regeneration Template, and Integra Omnigraft Dermal Rege
Timeline entries are records held by MedtechLedger for P900033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P900033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Integra Lifesciences Corp. | PMA approval | Mar 1, 1996 | FDA | |
| Integra Lifesciences Corp. | PMA supplement | Feb 25, 2026 | FDA | |
| Integra Lifesciences Corp. | PMA supplement | Sep 18, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Integra Lifesciences Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 105 Morgan Ln., Plainsboro, NJ, 08536
Sources and methodology
- Original FDA record: P900033/S115
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

